Medpace (MEDP) News
NASDAQ: MEDPHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
612.05+9.35 (+1.55%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MEDP news summary
We found 3 recent headlines mentioning Medpace (MEDP): 0 in the past week and 0 in the past 30 days, most often from Nasdaq. For price context, MEDP is up 1.55% at $612.05. The most recent story, "Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?", was published by Nasdaq on Sep 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Medpace headlines
- Is Revvity Stock a Buy as Growth Improves but Valuation Stays Rich?Revvity's raised 2026 outlook, Diagnostics growth and stronger cash flow brighten the setup, but premium valuation and software risks call for selectivity.NasdaqRVTY, DHR, MEDP
- Can AI Innovation and CRM Wins Boost Veeva Systems' Q2 Results?VEEV heads into Q2 with Falcon AI, Vault CRM wins and R&D Cloud growth in focus as revenue and EPS estimates point to double-digit gains.NasdaqVEEV, MEDP, IQV
- CRL Jumps 33.3% in the Past Month: Can This Strong Rally Keep Running?Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.NasdaqCRL, MEDP, IQV